IGC Pharma Future Growth
Future criteria checks 1/6
IGC Pharma is forecast to grow earnings and revenue by 0.1% and 10.1% per annum respectively while EPS is expected to grow by 18.6% per annum.
Key information
0.1%
Earnings growth rate
18.6%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 10.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 2 | -13 | N/A | -5 | 1 |
| 3/31/2026 | 1 | -11 | N/A | -6 | 2 |
| 3/31/2025 | 1 | -10 | N/A | -8 | 1 |
| 9/30/2024 | 1 | -13 | -5 | -5 | N/A |
| 6/30/2024 | 1 | -13 | -6 | -5 | N/A |
| 3/31/2024 | 1 | -13 | -6 | -5 | N/A |
| 12/31/2023 | 1 | -14 | -7 | -6 | N/A |
| 9/30/2023 | 1 | -11 | -7 | -6 | N/A |
| 6/30/2023 | 1 | -11 | -7 | -6 | N/A |
| 3/31/2023 | 1 | -12 | -8 | -7 | N/A |
| 12/31/2022 | 1 | -14 | -7 | -6 | N/A |
| 9/30/2022 | 1 | -14 | -8 | -7 | N/A |
| 6/30/2022 | 1 | -16 | -9 | -8 | N/A |
| 3/31/2022 | 0 | -15 | -8 | -7 | N/A |
| 12/31/2021 | 0 | -11 | -9 | -9 | N/A |
| 9/30/2021 | 0 | -11 | -9 | -9 | N/A |
| 6/30/2021 | 0 | -9 | -9 | -9 | N/A |
| 3/31/2021 | 1 | -9 | -12 | -11 | N/A |
| 12/31/2020 | 1 | -9 | -12 | -10 | N/A |
| 9/30/2020 | 1 | -8 | -14 | -11 | N/A |
| 6/30/2020 | 3 | -8 | -14 | -10 | N/A |
| 3/31/2020 | 4 | -7 | -13 | -9 | N/A |
| 12/31/2019 | 6 | -6 | -12 | -8 | N/A |
| 9/30/2019 | 6 | -5 | -9 | -7 | N/A |
| 6/30/2019 | 5 | -5 | -7 | -6 | N/A |
| 3/31/2019 | 5 | -4 | -3 | -3 | N/A |
| 12/31/2018 | 5 | -3 | -3 | -3 | N/A |
| 9/30/2018 | 4 | -2 | -2 | -2 | N/A |
| 6/30/2018 | 4 | -2 | N/A | -2 | N/A |
| 3/31/2018 | 2 | -2 | N/A | -2 | N/A |
| 12/31/2017 | 1 | -2 | N/A | -2 | N/A |
| 9/30/2017 | 1 | -2 | N/A | -1 | N/A |
| 6/30/2017 | 0 | -2 | N/A | -2 | N/A |
| 3/31/2017 | 1 | -2 | N/A | -1 | N/A |
| 12/31/2016 | 2 | -3 | N/A | -1 | N/A |
| 9/30/2016 | 3 | -3 | N/A | -1 | N/A |
| 6/30/2016 | 5 | -3 | N/A | 1 | N/A |
| 3/31/2016 | 6 | -3 | N/A | 0 | N/A |
| 12/31/2015 | 7 | -3 | N/A | 0 | N/A |
| 9/30/2015 | 9 | -4 | N/A | -1 | N/A |
| 6/30/2015 | 9 | -4 | N/A | -3 | N/A |
| 3/31/2015 | 8 | -5 | N/A | -3 | N/A |
| 12/31/2014 | 5 | -4 | N/A | -3 | N/A |
| 9/30/2014 | 3 | -4 | N/A | -3 | N/A |
| 6/30/2014 | 2 | -4 | N/A | -2 | N/A |
| 3/31/2014 | 2 | -3 | N/A | -2 | N/A |
| 12/31/2013 | 4 | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IGS1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IGS1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IGS1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IGS1's revenue (10.1% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: IGS1's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IGS1's Return on Equity is forecast to be high in 3 years time